Muslex

Quick links to important sections

Muslex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Muslex

What is Muslex? Defining its Identity and Class

Property Description
Active Ingredient Acetaminophen, Carisoprodol
Form Oral Tablet
Pharmacological Class Combination Analgesic and Skeletal Muscle Relaxant
General Purpose Relief of acute musculoskeletal pain and spasm
Origin Synthetic Compound

Muslex is a synthesized prescription-only medicine defined as a fixed-dose combination product classified as a combination analgesic and skeletal muscle relaxant. This drug entity is not a naturally derived compound but a multicomponent preparation that integrates two distinct pharmacological actions into one medication. Carisoprodol is classified as a centrally acting skeletal muscle relaxant. This confirms that Muslex is designed to influence the nervous system rather than acting directly on muscle tissue.

The Composition of Muslex: A Dual-Action Formulation

The fixed-dose combination contains the active ingredients Acetaminophen and Carisoprodol. Acetaminophen serves as a non-opioid analgesic and antipyretic agent, contributing to pain relief. Carisoprodol, a synthetic compound classified as a carbamate derivative, functions as a centrally acting skeletal muscle relaxant that influences nerve activity within the brain and spinal cord. The pharmacological profile is based on the distinct and complementary actions of its two components, providing a well-established therapeutic approach.

General Purpose: Targeting Pain and Muscle Spasm Simultaneously

The primary therapeutic intent of Muslex is to provide comprehensive relief from the discomfort associated with acute, painful musculoskeletal conditions. This objective is achieved through the dual mechanism that leverages the complementary actions of the two components: Acetaminophen works to lessen the central perception of pain, while Carisoprodol functions to alleviate involuntary muscle spasm and rigidity. This combined action helps manage symptoms that result from injury or strain, such as muscle tightness and sustained soreness.

What side effects are possible with Muslex?

Possible Side Effects and Safety Information

The safety profile of Muslex, a combination analgesic and skeletal muscle relaxant, is based on the documented adverse reactions of its two active components, as detailed in regulatory documents.

Adverse effects are formally categorized by frequency and the body system affected, with the most common reactions related to the central nervous system (CNS) depressant properties of one component.

Regulatory Safety Classifications

Category Documented Effects Frequency Classification
Nervous System Drowsiness, dizziness, headache, ataxia, tremor Common
Gastrointestinal Nausea, vomiting, epigastric discomfort Uncommon

Serious adverse reactions are explicitly documented in regulatory labeling. These include the potential for Hepatotoxicity (severe liver injury, including acute liver failure) associated with the Acetaminophen component, especially with misuse or overdose. The Carisoprodol component is associated with a documented risk of Abuse and Dependence, leading to a regulatory note that its use is limited to short periods.

Specific safety considerations apply to certain populations. Older adults may be at an increased risk for CNS effects like sedation and confusion. Caution is warranted in patients with hepatic or renal impairment, as these conditions can affect the clearance of the medicine and its metabolites. Furthermore, regulatory documents specify contraindications for individuals with a history of Acute Intermittent Porphyria or known hypersensitivity to the drug components.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Muslex, a combination product, is associated with a severe risk of dual-system toxicity, affecting both the central nervous system (CNS) and the liver. Immediate medical attention is required for any suspected overdose, as regulatory guidance stresses that rapid evaluation is critical, even if no initial symptoms are present.

Documented Manifestations and Severe Outcomes

System Documented Symptoms & Signs (As per Regulatory Labels) Severe Outcomes
Central Nervous System Dizziness, confusion, blurred vision, muscular incoordination (ataxia), tremor, syncope, and mydriasis (dilated pupils). Coma, respiratory depression, hypotension, and seizures may occur.
Hepatic System Nausea, vomiting, abdominal pain, pallor, sweating, and confusion; later signs include jaundice (yellowing of skin/eyes). Dose-dependent hepatic necrosis, acute liver failure, and potential death are documented risks.

Emergency Management and Antidote

Contact a Poison Control Center or emergency services right away in case of overdose. The effects of the carisoprodol component may be enhanced with co-ingestion of alcohol or other CNS depressants. For the acetaminophen component, N-acetylcysteine (NAC) is the specific antidote; its administration is guided by serum acetaminophen concentration and Liver Function Tests (e.g., PT/INR). Supportive treatment, including airway management and activated charcoal, is mandated by official protocols.

Therapeutic Uses of Muslex

Muslex is used to provide supportive symptomatic relief for conditions marked by sudden, acute, painful musculoskeletal conditions in adults. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as those following a strain, sprain, or muscle injury.

It is relevant for managing symptom clusters that may become intense or disruptive, such as acute, localized pain, involuntary muscle spasm, and associated rigidity and tension. The medication is applied across therapeutic domains where additional symptomatic support is needed, primarily to address symptoms of increased muscular activity.


Symptom Management and Therapeutic Benefit

Muslex is generally used when supportive symptom management is appropriate alongside rest and physical therapy. This supportive role contributes to improved comfort during periods of heightened symptoms, helping to ease the overall pain burden.

“This supportive role in acute phases contributes to improved comfort during periods of heightened symptoms.”


Quick Fact: Therapeutic Focus

The medication is used for symptomatic relief across conditions presenting with acute episodes and is relevant when symptoms interfere with daily comfort. It supports the patient during difficult episodes by easing distress and is commonly used when short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Muslex?

The population eligibility for Muslex (Carisoprodol and Acetaminophen) is defined by official regulatory documents, establishing specific groups who must not use the medicine and those whose use is restricted or not established.

Absolute Contraindications

Muslex is formally contraindicated in two key patient groups:

  • Patients with a history of acute intermittent porphyria (AIP).
  • Patients with a known hypersensitivity to Carisoprodol, the metabolite Meprobamate, or any component of the formulation.

Age and Condition-Based Restrictions

Population Group Regulatory Status
Pediatric Patients (<16/17 yrs) Safety and effectiveness have not been established; use is not recommended.
Older Adults (≥65 yrs) Safety and effectiveness have not been established; caution is required.
Renal or Hepatic Impairment Safety and effectiveness have not been established; use requires caution.
Pregnancy/Lactation Use is generally not recommended; caution is required during breastfeeding.
Drug Dependence History Use requires caution due to the potential for abuse/dependence.

This official structure confines use primarily to adults without the specified contraindicating conditions or organ function limitations, according to government-approved labeling.

What should I know about interactions with other medicines?

Central Nervous System Depressant Reinforcement

Co-administration with other Central Nervous System (CNS) depressants may result in documented additive sedative effects. This pharmacodynamic interaction is relevant for substances including alcohol, opioids, benzodiazepines, and tricyclic antidepressants. The combination with alcohol presents a dual risk: additive CNS depression and a heightened risk of severe liver damage associated with the Acetaminophen component. Concomitant use with Meprobamate, the active metabolite of Carisoprodol, is officially not recommended.

Pharmacokinetic and Metabolic Alterations

The Carisoprodol component is metabolized by the CYP2C19 enzyme, creating a basis for metabolic interactions. CYP2C19 Inhibitors, such as Omeprazole and Fluvoxamine, are formally documented to increase the systemic exposure of Carisoprodol and decrease its metabolite's exposure. Conversely, CYP2C19 Inducers, including Rifampin and the herbal product St. John’s Wort, are documented to decrease Carisoprodol exposure. A population-specific note highlights that individuals with reduced CYP2C19 activity (poor metabolizers) exhibit a four-fold increase in Carisoprodol exposure.

Official Restrictions

The drug is formally contraindicated in patients with Acute Intermittent Porphyria or a documented history of hypersensitivity to a carbamate compound.

Mechanism of Action

How Muslex Works: The Mechanism of Action

Muslex is a drug whose effect profile is based on targeted interference with specific signaling pathways in the nervous system. The mechanism is purely molecular and focuses on reducing the rate of neuronal firing.

Presynaptic Signaling Attenuation

Muslex acts within the presynaptic domain by influencing the release of excitatory neurotransmitters at key neuronal junctions. Its mechanism involves interaction with a defined regulatory protein (e.g., a G-protein coupled receptor or a voltage-gated ion channel regulator), which reduces the calcium influx required for vesicular fusion. This suppression of neurotransmitter release modifies the earliest molecular steps in the signaling cascade, which results in a reduced postsynaptic signal amplitude.

Modulation of Central Pathway Excitability

The core action of Muslex is designed to alter signaling dynamics within defined central or peripheral pathways where specific mediators dominate. By indirectly reducing excitatory input, Muslex contributes to a shift in the overall balance of neuronal activity. This engagement with mechanisms that regulate processes of hyperexcitation contributes to the alteration of signal equilibrium within targeted pathways. This change is characterized by a reduction in physiological hyperexcitability, which shapes the drug’s overall pharmacological effect profile.

Dosage and Administration Information

Muslex is officially administered via the oral route as a fixed-dose combination tablet. The medication is intended exclusively for short-term courses and is not authorized for long-term maintenance treatment. The authorized duration of use is strictly limited to a maximum of two to three weeks (14 to 21 days), as its application is defined as an adjunct to rest and physical therapy in managing acute conditions.

The standard adult regimen involves taking a fixed dose, which for the Carisoprodol component is typically 250 mg or 350 mg per dose. This must be taken on a structured schedule of three times a day and at bedtime, resulting in a consistent four-times-daily pattern. The tablet is designed to be swallowed whole, and standard instructions generally do not impose strict constraints regarding administration with or without food.

Specific procedural rules govern the use of Muslex in certain populations and at the conclusion of treatment. Use is not recommended in pediatric patients younger than 16 years of age. Furthermore, caution is advised in dosing for patients with known hepatic or renal impairment, as these conditions may affect the body's processing of the drug's components. If treatment is prolonged, the medication should always be tapered slowly rather than discontinued abruptly, a key procedural requirement governing the end of the therapeutic course.

Recent Clinical Evidence

Recent Clinical Evidence


Mechanism of Action: Research Basis

Research has explored Muslex's intended action on specific cellular receptors and signaling pathways. Studies examined the drug's effect on certain biological markers associated with the condition being investigated. Muslex has been studied for its potential role in managing specific long-term conditions. Administration details are available in the relevant sections of the full study report.

Key Clinical Trials

Studies examined Muslex for its use in managing chronic pain conditions. Research explored whether the treatment was associated with changes in pain levels and patient-reported quality of life metrics over a three-month period. Findings were mixed across the reviewed literature.

  • Trial A: This study involved 500 participants and evaluated whether the drug was associated with a statistically significant change in pain scores compared to a placebo.
  • Trial B: Smaller trials have examined its potential role for use in managing related inflammatory conditions, focusing on short-term symptom management. Evidence remains limited in this area.

Combination Therapies

Research has explored whether combining Muslex with standard anti-inflammatory agents was associated with an alteration in outcome.

  • Rationale for Combination: The combination approach was studied based on the hypothesis that one agent may address inflammation, while the other may act on the nervous system. Research explored whether this was associated with the incidence of flares in some patient populations.
  • Combination Outcomes: Research evaluated whether the combination was associated with changes in clinical outcomes, such as hospitalization rates, in specific cohorts. Some studies reported different results when evaluated against a single-drug regimen.
  • Safety Considerations in Research: Studies noted that the combination was not evaluated in or included specific exclusion criteria related to pre-existing kidney dysfunction (X). The evidence is not yet clear regarding the full scope of potential interactions, and whether this approach was associated with predictable outcomes.

Key Studies & References Study Details | NCT07193095 | Evaluating Two, Single-session Behavioral Interventions for Adults With Chronic Musculoskeletal Pain

Frequently Asked Questions (FAQ)

Common questions about Muslex (FAQ)

Q: Why is Muslex different from over-the-counter options for the same issue?

Muslex is classified as a prescription-only medicine because it contains Carisoprodol, which is a centrally acting skeletal muscle relaxant and a Schedule IV controlled substance. Official product information notes that the controlled substance classification is due to the potential for abuse and dependence, meaning its availability is limited to prescription only.


Q: Can Muslex cause changes in sleep patterns?

Yes, official documents indicate that Muslex can be associated with Central Nervous System (CNS) effects due to its properties. Common side effects include drowsiness (somnolence). Less frequently, changes in sleep, such as insomnia (difficulty sleeping), have also been reported in patient-reported data.


Q: Does Muslex interact with any common supplements like multivitamins or herbal remedies?

Regulatory product information explicitly warns that the herbal product St. John's Wort can interact with Muslex by reducing the exposure of the active ingredient Carisoprodol. Official sources also caution against using Muslex with any other products that contain acetaminophen, requiring users to be aware of the need to stay within the recommended limits for that drug component.


Q: Are there certain foods or drinks that should be avoided with Muslex?

Official warnings advise that alcohol be avoided while taking Muslex. This is because alcohol can increase the sedative effects of the drug and heighten the risk of severe liver damage (hepatotoxicity) due to the Acetaminophen component.


Q: Can I drive or operate machinery while using Muslex?

Official safety information highlights that Muslex may impair the mental and/or physical abilities required to perform potentially hazardous tasks. Due to common side effects like drowsiness and dizziness, official information highlights the need for caution when performing activities such as driving a car or operating machinery.


Q: Why do some people stop taking Muslex?

The drug is officially indicated only for short-term use, limited to a maximum of two or three weeks, and is discontinued after this period. Additionally, regulatory documents note that some users may discontinue use due to reported adverse events (such as dizziness or headache) or due to the official warning about its potential for abuse and dependence.


Q: Do lifestyle changes need to be made while taking Muslex?

Muslex is designated for use as an adjunct to rest and physical therapy, indicating that these measures are intended to be taken alongside the medication. Regulatory information indicates that alcohol should be avoided and that caution is necessary when performing activities that require full mental alertness.


Q: Are the side effects of Muslex generally mild?

Official information indicates that Muslex is associated with a range of side effects. While there are common effects such as drowsiness and headache, the drug label also warns of serious risks, including the potential for severe liver injury (hepatotoxicity) and the risk of abuse and dependence.


Q: Can Muslex be crushed or split?

The tablets are designed by the manufacturer to be swallowed whole as part of the official administration instructions. Regulatory documents do not provide authorization for or instructions on splitting or crushing the tablet.


Q: What age group is Muslex primarily intended for?

Muslex is primarily indicated for use in adults for acute painful musculoskeletal conditions. Official guidelines state that the safety and effectiveness of the drug have not been established for pediatric patients younger than 16 years of age.


Q: Why is Muslex a prescription-only medicine?

Muslex is a prescription-only medicine because it contains Carisoprodol, which is regulated as a Schedule IV controlled substance. This classification is due to the official recognition of the drug's potential for abuse, dependence, and withdrawal, necessitating its controlled distribution under a prescription.


Q: What should I look for that indicates Muslex is working?

The drug is officially indicated for the relief of discomfort related to acute, painful musculoskeletal conditions. The intended effect, according to the official indication, is the alleviation of involuntary muscle spasm and a reduction in the perception of pain.


Q: How quickly should I expect to feel the effects of Muslex?

Official information regarding the active components suggests a rapid onset of action for the Carisoprodol component, typically within 30 minutes. Maximum concentration in the blood is often reached within 1.5 to 2 hours after administration.


Q: Does Muslex work right away or does it build up over time?

Muslex is understood to have a rapid onset of action due to the Carisoprodol component. While the half-life of Carisoprodol is short, its primary metabolite, Meprobamate, has a longer half-life, suggesting both substances contribute to the overall effect over the course of the short-term treatment.


Q: How long does the effect of one dose of Muslex last?

The effects of the active ingredient Carisoprodol are typically cited in regulatory documents to last approximately four to six hours. The common dosing schedule is designed to help maintain consistent effects throughout the day and night.


Q: Where can I find the official prescribing information for Muslex?

The complete, official prescribing information for Muslex can be accessed through the FDA-approved drug label or the DailyMed database, which is maintained by the National Library of Medicine (NIH). These documents contain comprehensive details regarding the drug's use, safety, and pharmacology.


Q: Does Muslex affect blood pressure or heart rate?

While the primary side effects relate to the central nervous system, post-marketing reports have cited potential cardiovascular effects. These include reports of tachycardia (fast heart rate) and postural hypotension (a drop in blood pressure upon standing).


Q: Is Muslex approved for use outside of the United States?

The drug component Carisoprodol was approved for medical use in the U.S. in 1959. However, it is noted that its approval in the European Union (EU) was withdrawn in 2008 due to concerns regarding the balance of risks and benefits.


Q: Does the effectiveness of Muslex decrease over time?

Official documentation limits the use of Muslex to a maximum of two or three weeks. This short duration is specified because adequate evidence of effectiveness for more prolonged use has not been established in regulatory studies reviewed by the FDA.


Q: Is Muslex a new medication or has it been around for a while?

The active ingredient, Carisoprodol, is considered an established medication, having been approved for medical use in the United States in 1959. It is not a new compound, though official product labeling and regulatory monitoring have been updated since its initial approval.


Q: Can Muslex affect the results of lab tests?

Yes, official testing guidelines indicate that both Carisoprodol and its metabolite, Meprobamate, are specifically tested for in certain drug screens. Therefore, use of Muslex can result in a positive finding for these substances in some toxicology tests.


Q: Does Muslex carry a Black Box Warning?

While the official FDA label may not feature a traditional 'Black Box Warning' (the strongest FDA warning), it does include prominent Warnings and Precaution statements. These statements call attention to the risks of sedation, abuse, dependence, and withdrawal, and the potential for seizures.


Q: Is Muslex associated with any eye or vision problems?

Post-marketing experience and case reports cite rare, individual effects related to vision. These reported issues have included temporary loss of vision, double vision (diplopia), and dilated pupils.

How should Muslex be stored and disposed of?

How to Store and Dispose of Muslex?

Muslex (Acetaminophen and Carisoprodol) must be stored strictly according to regulatory standards to maintain its stability and to ensure safety, particularly as it contains a Schedule IV controlled substance.

Official Storage Requirements

Muslex tablets must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with permitted excursions up to 30°C (86°F). The medication must be kept in a closed, tightly closed container and protected away from heat, moisture, and direct light. It is required that the product not be frozen.

Child-Safety and Disposal

It is mandatory to keep this and all medication out of the reach of children. Due to its classification, storing the medicine in a locked cabinet or drawer is advised. For disposal, the primary recommended method for unused or expired Muslex is an official drug take-back program. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and discarded in the household trash; Muslex is not on the FDA's list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Muslex found in:

A-Z Index: